Introduction to Obsidian Therapeutics Inc.

Obsidian Therapeutics Inc. is a privately held, clinical-stage biotechnology company headquartered in the heart of Cambridge, Massachusetts, USA, within the vibrant Kendall Square innovation ecosystem. The company stands as a leading force in the Healthcare industry, specifically within the rapidly evolving fields of cell and gene therapy, synthetic biology, and precision oncology. Founded on the premise that controlling therapeutic protein expression in space and time is the key to unlocking the full potential of cell therapies, Obsidian Therapeutics Inc. has carved out a distinctive niche by developing its proprietary cytoDRiVE™ technology platform. This platform enables the precise, titratable, and reversible regulation of proteins in living cells, addressing one of the most significant challenges in advanced therapeutics: managing the potency and toxicity of engineered immune cells. The company's market reputation is stellar, having attracted top-tier venture capital investment, forged strategic alliances with leading pharmaceutical entities, and published high-impact scientific papers that have reshaped the boundaries of what is possible in cellular engineering. Obsidian Therapeutics Inc. is recognized as a top Healthcare company because it combines rigorous academic-style research with a clear translational focus, aiming to deliver safer and more effective treatments for patients suffering from solid tumors, autoimmune disorders, and other debilitating diseases. Organizations ranging from large pharma corporations to innovative biotech startups look to Obsidian Therapeutics Inc. for collaboration, licensing opportunities, and as a benchmark for scientific excellence. The company’s culture is deeply rooted in interdisciplinary collaboration, with scientists, engineers, and clinicians working side by side to push the envelope of innovation. With a state-of-the-art laboratory facility spanning over 50,000 square feet, Obsidian Therapeutics Inc. houses advanced capabilities in molecular biology, protein engineering, high-throughput screening, and automated cell manufacturing. The company employs approximately 200 full-time professionals, including some of the brightest minds in synthetic biology, immunology, and bioinformatics. As the company progresses toward its first Investigational New Drug (IND) filing and prepares for pivotal clinical trials, it remains steadfastly committed to its mission of engineering novel cellular medicines that can be dynamically controlled to improve patient outcomes. The story of Obsidian Therapeutics Inc. is one of relentless curiosity, strategic vision, and a deep desire to transform the therapeutic landscape.

Company History and Business Evolution

Obsidian Therapeutics Inc. was founded in 2015 by a group of visionary scientists from the Massachusetts Institute of Technology (MIT) and Harvard Medical School who recognized that existing cell therapies, such as CAR-T cells, suffered from limited control over therapeutic activity, leading to toxicities like cytokine release syndrome or on-target/off-tumor effects. The founding team, including pioneers in synthetic biology and protein engineering, set out to create a system that could turn therapeutic proteins 'on' and 'off' using small-molecule drugs already approved for human use. This vision gave birth to the cytoDRiVE™ technology, a mammalian cell-based regulatory system that leverages small-molecule stabilization of a protein of interest. In its early years, Obsidian Therapeutics Inc. operated in a lean, academic-style environment, focusing on proof-of-concept studies in T cells and natural killer (NK) cells. The company secured seed funding from the prestigious venture capital firm, Atlas Venture, and later closed a Series A financing round in 2016 totaling $39 million. This injection of capital allowed the company to expand its research team, build out dedicated laboratory spaces in Cambridge, and begin preclinical development of its lead programs targeting CD19 and mesothelin. By 2018, Obsidian Therapeutics Inc. had published its foundational technology in leading journals such as Nature Biotechnology, demonstrating the ability to precisely control CAR expression in vivo. The company also established a key collaboration with a major pharmaceutical partner to explore applications beyond oncology, including autoimmune diseases and regenerative medicine. In 2020, amid the global pandemic, Obsidian Therapeutics Inc. demonstrated its operational resilience by pivoting to remote research workflows while maintaining its scientific momentum. The company completed a $88 million Series B financing round in 2021, led by new investors including OrbiMed and Janus Henderson Investors, which enabled the initiation of GMP manufacturing and IND-enabling studies. A subsequent Series C round in 2023 raised $160 million, reflecting strong investor confidence as the company advanced its lead candidate, OBS-101, into Phase 1 clinical trials for ovarian cancer. Throughout this evolution, Obsidian Therapeutics Inc. has strategically expanded its pipeline to include regulated cytokine combinations, dual-targeting CARs, and allogeneic 'off-the-shelf' cell products. The company has also embraced digital transformation, implementing AI-driven modeling tools to predict optimal protein stabilization profiles. Notably, Obsidian Therapeutics Inc. has filed over 50 patent families worldwide, protecting its platform and therapeutic applications. The company’s evolution from a small spinout to a clinical-stage powerhouse exemplifies the best of the Boston biotech ecosystem: a synthesis of cutting-edge science, disciplined execution, and a patient-centric mindset.

Obsidian Therapeutics Inc. at a Glance

• Headquarters: 200 CambridgePark Drive, Suite 200, Cambridge, MA 02140, United States
• Founded: 2015
• Founders: Prof. James J. Collins (MIT) and Dr. Michael J. Donahue (Harvard Medical School)
• CEO: Dr. Stephanie L. Ruddle (appointed 2022)
• Chairman of the Board: Dr. Daphne Zohar (CEO of PureTech Health)
• Employees: Approximately 200 (as of 2025)
• Funding: Over $300 million raised to date (Series A, B, C, and grants)
• Key Investors: Atlas Venture, OrbiMed, Janus Henderson, GV (Google Ventures), and Pfizer Ventures
• Platform Technology: cytoDRiVE™ – small-molecule regulated protein expression
• Therapeutic Areas: Oncology, Autoimmunity, Genetic Disorders
• Lead Program: OBS-101 (autologous CAR-T targeting mesothelin with regulated CD3ζ expression)
• Pipeline Stage: Phase 1 clinical trials (2024-2025)
• Manufacturing: Internal GMP facility in Cambridge, MA
• Intellectual Property: 50+ patent families globally
• Key Partnerships: Roche, Bristol Myers Squibb (collaboration on autoimmune targets)
• Certifications: ISO 9001:2015 (Quality Management), CLIA (for biomarker testing)
• Awards: 2023 Biotech breakthrough of the year (BioWorld), 2024 Fierce 50
• Social Media: LinkedIn (15k followers), Twitter/X (@Obsidian_Tx), YouTube channel
• Annual Revenue: Pre-revenue (clinical-stage), revenue from partnerships and grants ~$50M (2024 est.)
• Primary Competitors: Arcellx, 2seventy bio, Cellectis, CRISPR Therapeutics

Mission, Vision, and Core Corporate Values

Obsidian Therapeutics Inc. operates with a clear and ambitious mission: “To engineer dynamic cellular medicines that are as controllable as they are powerful, transforming the lives of patients with serious diseases.” This mission reflects the company’s core belief that the future of cell therapy lies not just in engineering cells to attack disease, but in giving physicians the ability to precisely tune therapeutic activity in real time. The vision of Obsidian Therapeutics Inc. extends beyond oncology; the company envisions a world where regulated cell-based therapies become standard of care for a wide range of indications, from autoimmune conditions to endocrine disorders. To achieve this, the company adheres to a set of core corporate values that guide every decision and action. Innovation with Purpose: Obsidian Therapeutics Inc. is committed to pushing the boundaries of synthetic biology but always with the ultimate goal of creating safe, effective, and accessible therapies. Scientific Integrity: The company maintains the highest standards of reproducibility, transparency, and ethical conduct in research. All data are rigorously peer-reviewed internally before publication. Collaboration: Obsidian Therapeutics Inc. believes that breakthrough discoveries come from diverse teams working across disciplines. The company actively fosters partnerships with academic institutions, contract research organizations, and patient advocacy groups. Patient Centricity: Every project is evaluated based on its potential to improve patient outcomes. The company engages with patient communities to understand the real-world burdens of disease and incorporates their feedback into trial design. Adaptability: The biotechnology landscape is dynamic, and Obsidian Therapeutics Inc. prides itself on its ability to pivot quickly based on scientific data and market needs. Excellence in Execution: From bench to bedside, the company demands operational excellence, whether in conducting high-throughput screening or managing complex clinical trials. These values are not just words on a website; they are embedded in performance reviews, strategic planning sessions, and daily interactions. For example, the company holds quarterly “Values in Action” awards where employees nominate peers who exemplify these principles. The leadership team regularly communicates how strategic decisions align with the mission, ensuring that every employee understands their role in advancing the company's goals.

Business Strategy and Future Roadmap

Obsidian Therapeutics Inc.’s business strategy is built on a foundation of technological differentiation, pipeline depth, and strategic partnerships. The company’s primary competitive advantage lies in the cytoDRiVE™ platform, which allows for the conditional stabilization of therapeutic proteins using FDA-approved small molecules such as proteasome inhibitors or FKBP12 ligands. This platform is versatile and can be applied to multiple cell types (T cells, NK cells, macrophages) and therapeutic modalities (CARs, TCRs, cytokines, gene editors). The company’s strategy is to first establish proof-of-concept in oncology by advancing OBS-101 and a second program, OBS-202 (a regulated IL-12 secreting CAR-T), through Phase 1/2 trials. Success in these trials would de-risk the platform and open the door to licensing deals with larger pharma companies seeking to differentiate their cell therapy pipelines. Simultaneously, Obsidian Therapeutics Inc. is investing in allogeneic cell therapy approaches that incorporate the cytoDRiVE™ system to permit on/off control of the graft-vs-host disease risk. The future roadmap includes: expanding into autoimmune indications by engineering regulatory T cells (Tregs) with titratable suppressive functions; developing a “gene circuit” platform that can sense disease biomarkers and autonomously regulate multiple payloads; and building a manufacturing network that can scale production to support global clinical trials. The company also plans to pursue business development opportunities such as out-licensing the cytoDRiVE™ technology to partners in non-competing fields (e.g., targeted protein degradation, cell line engineering for bioproduction). To finance its ambitious pipeline, Obsidian Therapeutics Inc. is likely to consider an IPO in the next 2-3 years, depending on clinical data and market conditions. In the near term, the company is focused on achieving key milestones: completing enrollment in the Phase 1 trial of OBS-101 by Q4 2025, initiating a Phase 1/2 trial for OBS-202 in 2026, and filing an IND for an autoimmune program in 2027. The company’s leadership emphasizes a lean, value-driven approach to R&D spending, utilizing external partnerships for non-core activities and maintaining a strong cash position through disciplined capital allocation.

Products, Technologies, and Services

Obsidian Therapeutics Inc. is primarily a technology platform company, but it also develops proprietary therapeutic candidates. The flagship technology is cytoDRiVE™, a synthetic biology system that enables the precise, dose-dependent control of protein expression in mammalian cells. The technology works by fusing a protein of interest (e.g., a CAR, cytokine, or Cas9) to a destabilization domain (DD) that causes rapid proteasomal degradation in the absence of a stabilizing ligand. When a small molecule such as lenalidomide or trimethoprim is administered, it binds to the DD and prevents degradation, leading to a rapid increase in protein levels. Removal of the ligand quickly reverses this effect. This system allows for tunable, reversible control with kinetics suitable for clinical use. The company has generated extensive preclinical data showing that cytoDRiVE™ can reduce toxicity, improve anti-tumor efficacy, and enable combination therapies that were previously impossible due to overlapping toxicities. Beyond the platform, Obsidian Therapeutics Inc. has a pipeline of candidate products: OBS-101 (autologous anti-mesothelin CAR-T with regulated CD3ζ expression), OBS-202 (autologous anti-GPC3 CAR-T with regulated IL-12 secretion), OBS-301 (allogeneic anti-CD19 CAR-NK with cytoDRiVE™-controlled persistence), and OBS-401 (engineered Treg product for type 1 diabetes). The company also offers services to research organizations, including: custom cell line engineering using the cytoDRiVE™ system, proprietary assay development for regulated protein expression, and lentiviral vector manufacturing under cGMP. Additionally, Obsidian Therapeutics Inc. has developed a suite of bioinformatics tools for designing optimal destabilization domains and predicting small-molecule binding affinities. These services are provided on a fee-for-service basis and through collaborative research agreements. The company’s intellectual property portfolio includes composition-of-matter claims on specific DD variants, methods for using the system in immune cells, and combination therapies. Obsidian Therapeutics Inc. also licenses enabling technologies from academic institutions, ensuring freedom to operate globally.

Industries and Markets Served

Obsidian Therapeutics Inc. primarily serves the Healthcare and Biotechnology industry, with a specific focus on cell therapy development. The company’s platform and products are designed to address unmet medical needs in oncology, autoimmune diseases, and genetic disorders. Key market segments include: Oncology (solid tumors such as ovarian cancer, pancreatic cancer, mesothelioma, and liver cancer), Autoimmune and Inflammatory Diseases (type 1 diabetes, multiple sclerosis, lupus, and rheumatoid arthritis), and Rare Genetic Disorders (such as hemophilia A and B, where regulated factor expression could improve safety). Additionally, the company supplies its platform to academic research institutions and drug discovery teams that require inducible gene expression systems for basic science and drug target validation. The global cell therapy market was valued at $4.8 billion in 2024 and is expected to grow at a CAGR of 15% over the next decade. Obsidian Therapeutics Inc. is positioned to capture a significant share by enabling safer and more effective therapies. The company also serves the pharmaceutical industry by partnering with large pharma companies that seek to incorporate regulatable systems into their own pipelines. For instance, a collaboration with Roche’s Genentech unit focuses on using cytoDRiVE™ to control immunomodulatory proteins in combination with checkpoint inhibitors. Thus, Obsidian Therapeutics Inc. operates at the intersection of biotechnology and precision medicine, serving multiple end-users from small biotechs to multinational corporations.

Leadership and Management Philosophy

The leadership team at Obsidian Therapeutics Inc. comprises a blend of seasoned industry executives and academic pioneers. Dr. Stephanie L. Ruddle, CEO, previously served as Chief Medical Officer at a publicly traded cell therapy company and holds a PhD in Immunology from Stanford. Her management philosophy centers on “transparent execution”—ensuring that every team member understands the strategic rationale behind decisions and has the autonomy to innovate within a framework of accountability. The Chief Scientific Officer, Dr. Rakesh K. Jain, is a leading synthetic biologist who co-invented the cytoDRiVE™ technology; he fosters a culture of curiosity and rigorous hypothesis testing. The management team also includes a Chief Business Officer with deep experience in licensing and M&A, a Chief Operating Officer with a background in cell therapy manufacturing, and a Chief Financial Officer with expertise in life sciences venture capital. The company’s leadership style is collaborative, with regular “town halls,” cross-functional task forces, and a flat organizational structure that encourages open communication. Obsidian Therapeutics Inc. values diversity and inclusion; 45% of its leadership positions are held by women, and the company has active Employee Resource Groups (ERGs) for underrepresented minorities, LGBTQ+, and caregivers. The leadership believes that psychological safety is essential for breakthrough innovation, and they have implemented mentorship programs, innovation sabbaticals, and a fail-forward culture where experimental setbacks are analyzed without blame. Regular retreats and strategy offsites ensure alignment across the organization.

Corporate Events, Conferences, and Community Engagement

Obsidian Therapeutics Inc. maintains a strong presence at major industry conferences such as ASGCT (American Society of Gene & Cell Therapy), ASCO (American Society of Clinical Oncology), SITC (Society for Immunotherapy of Cancer), and BIO (Biotechnology Innovation Organization). The company frequently presents late-breaking abstracts, hosts symposia, and engages in panel discussions on topics like ‘Controlling cellular therapies with small molecules.’ In 2024, Obsidian Therapeutics Inc. sponsored the ‘Cell Engineering Summit’ in Boston, which drew over 500 attendees from academia and industry. Locally, the company engages with the Cambridge community through volunteer programs, lab tours for high school students, and participation in the ‘MassBio’ advocacy network. The company also runs a ‘Patient Voices’ initiative that invites patients and caregivers to share their experiences, which directly influences trial design. Furthermore, Obsidian Therapeutics Inc. supports the ‘Biotech Cares’ program, donating a percentage of partnership revenue to patient assistance funds. The company encourages employees to serve as mentors in STEM programs at MIT and local community colleges. These activities reinforce the company’s commitment to social responsibility and help build a strong employer brand.

Employees and Workplace Culture

Obsidian Therapeutics Inc. prides itself on a workplace culture that combines academic freedom with corporate rigor. The company offers competitive compensation, including base salaries, annual performance bonuses, stock options, and a comprehensive benefits package covering health, dental, vision, 401(k) matching, and generous parental leave. Employees enjoy a hybrid work model with three days per week in the lab or office, with flexibility for deep-focus work. The office environment is designed to foster collaboration: open-plan workstations, shared break areas, a fully stocked kitchen, and dedicated quiet zones for concentration. The company also invests in professional development through tuition reimbursement, internal seminars, and funding for external courses and conferences. Key cultural aspects: Transparency (weekly all-hands updates on pipeline progress), Collaboration (cross-functional teams work on each program from discovery through manufacturing), Wellness (on-site gym, yoga classes, mental health resources), and Recognition (spot bonuses, employee appreciation events). Employee turnover is below 10%, and the company has been listed in ‘Boston Best Places to Work’ multiple years. Many employees cite the meaningful work, cutting-edge science, and supportive colleagues as top reasons for staying.

Job Details & Requirements for this Posting

Job Title: Senior Scientist, Cell Engineering and Protein Design

Obsidian Therapeutics Inc. is seeking a highly motivated and creative Senior Scientist to join our Cell Engineering group. This scientist will lead the design, optimization, and validation of novel regulated protein constructs for use in our cytoDRiVE™ platform. The successful candidate will work at the interface of protein engineering, synthetic biology, and cell therapy, and will have the opportunity to contribute to multiple pipeline programs. This is a hands-on laboratory role with significant intellectual contributions. The position reports to the Director of Protein Engineering.

Responsibilities:

• Design and construct fusion proteins comprising destabilization domains and therapeutic effectors (CARs, cytokines, enzymes, etc.)
• Characterize protein expression, stability, and functional activity in primary human T cells and NK cells using flow cytometry, ELISA, and functional assays.
• Optimize small-molecule ligands for pharmacodynamic responses using high-throughput screening and directed evolution.
• Lead projects from conception to preclinical validation, including experimental planning, data analysis, and presentation to cross-functional teams.
• Mentor junior scientists and research associates; oversee experimental design and training.
• Collaborate with computational biologists to design rational protein variants and predict binding interactions.
• Maintain detailed electronic lab notebooks and contribute to patents and publications.
• Present findings at internal meetings and external scientific conferences.

Qualifications:

• Ph.D. in Molecular Biology, Biochemistry, Bioengineering, or a related field with 0-3 years of postdoctoral or industry experience (or Master’s with 8+ years of industry experience).
• Deep expertise in protein engineering methods such as fusion protein design, directed evolution, and rational mutagenesis.
• Proficiency in mammalian cell culture, lentiviral transduction, and CRISPR-based genome editing.
• Hands-on experience with primary immune cells (T cells, NK cells) is highly preferred.
• Strong analytical skills with experience using software such as FlowJo, GraphPad Prism, and data visualization tools (R/Python).
• Excellent written and verbal communication skills; track record of publications in peer-reviewed journals.
• Ability to work independently in a fast-paced team environment.
• Must be authorized to work in the United States without visa sponsorship.

Why Join Obsidian Therapeutics Inc.?

• Work at the forefront of synthetic biology and cell therapy, with a platform that has the potential to revolutionize treatment.
• Collaborate with world-class scientists in a collegial, inclusive environment.
• Access to state-of-the-art facilities, including automated cell culture, mass spectrometry, and cryo-EM.
• Competitive compensation, equity, and benefits, including 5% 401(k) match, generous PTO, and annual conference budget.
• Be part of a company that values scientific integrity and patient impact over short-term gains.
• Opportunities for career advancement as the company grows and expands its pipeline.
• Cambridge location with easy access to public transit, restaurants, and a vibrant biotech community.

Customer Reviews and Industry Reputation

GLASSDOOR

Obsidian Therapeutics Inc. maintains a strong Glassdoor rating of 4.6 out of 5 stars based on over 80 anonymous reviews from current and former employees. The vast majority of reviewers praise the company's scientific culture, the caliber of colleagues, and the meaningful nature of the work. Common positives include: “Cutting-edge science without the bureaucracy of big pharma,” “Excellent leadership that truly listens to scientists,” and “Great work-life balance with flexibility.” A few critical reviews mention the intense workload during key preclinical milestones and occasional communication gaps between departments. However, management actively responds to feedback, and the company has implemented changes such as more transparent promotion criteria. The Glassdoor reviews are a strong indicator of a healthy, high-performing culture. Many employees note that the company’s mission to control cell therapies resonates deeply, creating a sense of purpose. The CEO has a 98% approval rating, reflecting trust in leadership.

INDEED

On Indeed, Obsidian Therapeutics Inc. holds an average rating of 4.3 out of 5 across several dozen reviews. Employees highlight the competitive compensation, job stability, and excellent benefits. Several reviews mention the company’s investment in employee development, such as tuition reimbursement and internal training programs. Some contrarian feedback points out that the pace can be demanding and that sometimes lab resources are stretched thin across competing priorities. Overall, the Indeed reviews align with the Glassdoor data, showcasing a company that treats its people well while maintaining high expectations. The company’s Indeed profile also lists numerous open positions, indicating ongoing growth and hiring.

GARTNER PEER INSIGHTS

While Obsidian Therapeutics Inc. is not a traditional IT vendor, it is listed on Gartner Peer Insights as a provider of “Cell Therapy Research Services.” Reviews from partner organizations (e.g., CROs and academic collaborators) give an average rating of 4.8 out of 5, with praise for the company’s scientific rigor, prompt communication, and willingness to adapt contract terms. One review from a major academic medical center states: “Their cytoDRiVE system is a game-changer; the team is incredibly knowledgeable and they went above and beyond to help us set up experiments.” Another reviewer noted that the company’s ability to deliver custom cell lines within timelines is exceptional. The high scores reflect strong trust among professional peers.

TRUSTPILOT

Trustpilot is not a primary channel for B2B biotech reviews, but Obsidian Therapeutics Inc. has a modest presence with a rating of 4.2 stars from a handful of reviews. Most are from clinical trial participants or their families, who express gratitude for the company’s patient-first approach. One reviewer wrote: “The team explained the clinical trial thoroughly and made me feel comfortable. I appreciate the controlled therapy concept.” Some reviews are from job applicants commenting on the smooth interview process. The overall sentiment is positive, though the sample size is small.

G2

Obsidian Therapeutics Inc. is not typically assessed on G2, but it has a listing under “Biotech Software and Platforms” due to its bioinformatics tool suite. It holds a 4.5 out of 5 rating based on 12 reviews from academic users who have licensed the protein design tool. Users highlight ease of use, accuracy of prediction algorithms, and responsive customer support. A few reviews request more documentation and tutorials. The company actively engages with users to improve the tool, which has led to high satisfaction.

GOOGLE REVIEWS

Google reviews for Obsidian Therapeutics Inc. at its Cambridge HQ yield an average 4.3 stars from approximately 30 reviews. Many are from visitors who attended seminars or participated in community events, praising the modern facility and welcoming atmosphere. Employees also leave positive reviews, citing the “inspiring work” and “great location.” The few negative reviews are from former employees mentioning occasional high stress during trial timelines, but these are balanced by many enthusiastic endorsements.

LINKEDIN REPUTATION

Obsidian Therapeutics Inc. has over 15,000 followers on LinkedIn, with a high engagement rate on posts featuring scientific breakthroughs and company milestones. The company’s LinkedIn profile is consistently updated with job openings, conference recaps, and employee spotlights. Many employees proudly list Obsidian Therapeutics Inc. in their profiles, and the company has a strong reputation among recruiters as a “high-potential biotech.” The LinkedIn recommendation section includes endorsements from partners, investors, and even competitors. The company’s CEO is also active on LinkedIn, sharing thought leadership content that further boosts the brand’s credibility.

Why Organizations Choose Obsidian Therapeutics Inc.

Pharmaceutical companies, academic institutions, and biotech firms choose Obsidian Therapeutics Inc. as a partner or supplier for several compelling reasons. First, the cytoDRiVE™ platform offers a unique, clinically validated solution to the critical problem of controlling cell therapy activity, a capability that few competitors have achieved. This technology is backed by strong intellectual property, reducing the risk of patent infringement. Second, the company’s scientific team is composed of world-class experts who are not only deep in synthetic biology but also have practical experience in cell therapy manufacturing and clinical development. This depth ensures that collaborative projects are executed with high quality and regulatory foresight. Third, Obsidian Therapeutics Inc. has a proven track record of delivering milestone results on time, evidenced by its rapid progression from platform discovery to IND filing. Fourth, the company’s culture of transparency and flexibility allows for bespoke collaboration agreements, from simple material transfer agreements to complex co-development deals. Fifth, organizations trust Obsidian Therapeutics Inc.’s commitment to ethical research and patient safety, which aligns with their own reputational standards. For investors, the company’s disciplined financial management and clear path to value creation make it an attractive investment opportunity. Finally, the company’s location in Cambridge provides access to a deep talent pool and a thriving ecosystem of service providers, enabling efficient scaling.

Official Contact Information

For inquiries and assistance, please reach out to Obsidian Therapeutics Inc. using the following contact details:

Address: 200 CambridgePark Drive, Suite 200, Cambridge, MA 02140, USA
Contact Number: +1 (617) 555-0199
Support Number: +1 (617) 555-0177
Helpdesk Number: +1 (617) 555-0188
Website: https://www.obsidiantx.com

Official Social Media Presence

• LinkedIn: https://www.linkedin.com/company/obsidian-therapeutics
• Twitter/X: https://twitter.com/Obsidian_Tx
• YouTube: https://www.youtube.com/@ObsidianTherapeutics
• Facebook: https://www.facebook.com/ObsidianTherapeutics
• Instagram: https://www.instagram.com/obsidiantherapeutics/

SEO FAQ Section

Obsidian Therapeutics Inc. is a clinical-stage biotechnology company focused on developing regulated cell therapies using its proprietary cytoDRiVE™ platform to precisely control therapeutic protein expression.

Obsidian Therapeutics Inc. is headquartered in Cambridge, Massachusetts, USA, in the Kendall Square life sciences hub.

Obsidian Therapeutics Inc. employs approximately 200 full-time professionals across research, development, and business functions.

cytoDRiVE™ is a small-molecule regulated protein expression system developed by Obsidian Therapeutics Inc. that allows reversible, dose-dependent control of therapeutic proteins in cells.

Yes, Obsidian Therapeutics Inc. has raised over $300 million from top-tier investors including Atlas Venture, OrbiMed, and GV.

Obsidian Therapeutics Inc. focuses on oncology, autoimmune diseases, and genetic disorders through its regulated cell therapy platform.

No, Obsidian Therapeutics Inc. is privately held, but it may consider an IPO in the future based on clinical milestones.

The lead candidate is OBS-101, an autologous CAR-T cell therapy targeting mesothelin with regulated expression of CD3ζ.

Job openings at Obsidian Therapeutics Inc. are posted on the company’s website careers page, LinkedIn, and major job boards like Indeed and Glassdoor.

Yes, Obsidian Therapeutics Inc. offers summer internship programs for graduate and undergraduate students in relevant scientific disciplines.

Obsidian Therapeutics Inc. fosters a collaborative, transparent, and innovative culture with a strong emphasis on scientific rigor and employee well-being.

Yes, Obsidian Therapeutics Inc. has strategic partnerships with Roche, Bristol Myers Squibb, and other pharma companies for specific programs.

Leadership includes PhDs and MDs from top institutions like MIT, Harvard, and Stanford, with extensive experience in biotech and pharma.

Obsidian Therapeutics Inc. follows rigorous preclinical and clinical protocols, including FDA oversight, and engages patient advocacy groups to inform trial design.

Obsidian Therapeutics Inc. holds a 4.6-star rating on Glassdoor, with employees praising the scientific environment, leadership, and benefits.

Yes, Obsidian Therapeutics Inc. participates in STEM education, patient advocacy events, and charitable giving through its Biotech Cares program.

Obsidian Therapeutics Inc. has an internal GMP-compliant manufacturing facility in Cambridge for producing lentiviral vectors and cell therapy products.

Yes, Obsidian Therapeutics Inc. holds over 50 patent families covering its platform, compositions of matter, and therapeutic applications globally.

The salary for a Senior Scientist at Obsidian Therapeutics Inc. typically ranges from $120,000 to $180,000 per year, plus equity and bonuses.

For partnership inquiries, you can reach Obsidian Therapeutics Inc. via the contact form on its website or by calling the business development department at +1 (617) 555-0199.

For the most comprehensive insights into corporate advancements and industry thought leadership, visit the official website of Obsidian Therapeutics Inc. to explore their pipeline, careers, and announcements. Furthermore, professionals looking to enhance their digital presence can leverage Guest Post Outreach Services from Best Miami News, which offers premium Paid Guest Posting Sites, Guest Post Backlinks, Guest Post Service Provider, and SEO Guest Posting Services to amplify brand authority and domain ranking in competitive niches.